ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
2026 ARDC Annual Survey is now open!

The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your interaction with the ARDC and use of our national research infrastructure and services. The survey will take approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure services including Reasearch Link Australia.

We will use the information you provide to improve the national research infrastructure and services we deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program.

Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.

Complete the 5 min survey now by clicking on the link below.

Take Survey Now

Thank you.

  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : Diabetes prevention
Scheme : Programs
Status : Closed
Clear All
Filter by Field of Research
Nutrigenomics and personalised nutrition (3)
Autoimmunity (1)
Clinical Pharmacology and Therapeutics (1)
Clinical sciences not elsewhere classified (1)
Neurosciences not elsewhere classified (1)
Nutrition and dietetics not elsewhere classified (1)
Nutritional science (1)
Oncology and Carcinogenesis (1)
Respiratory Diseases (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (11)
Filter by Status
Closed (11)
Filter by Scheme
Programs (11)
Filter by Country
Australia (4)
United States of America (1)
Filter by Australian State/Territory
VIC (4)
  • Researchers (0)
  • Funded Activities (11)
  • Organisations (19)
  • Funded Activity

    Advances In Clinical Trials Research And Evidence Based Decision Making

    Funder
    National Health and Medical Research Council
    Funding Amount
    $6,712,859.00
    Summary
    The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arriv .... The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arrive at better evidence.
    Read more Read less
    More information
    Funded Activity

    Generating The Evidence For New Strategies To Combat Cardiovascular Diseases.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $12,809,917.00
    Summary
    The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patien .... The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patients, doctors, consumers and policy makers new options for disease prevention.
    Read more Read less
    More information
    Funded Activity

    Prevention And Treatment Of Chronic Heart And Kidney Disease Via Epidemiological, Pharmacol Device And Cell-Based Approaches

    Funder
    National Health and Medical Research Council
    Funding Amount
    $5,795,334.00
    Summary
    Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identi .... Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identify ways to better treat patients with existing disease; (3) focus on the effect of heart failure on the kidney and vice versa via early diagnosis and treatment strategies
    Read more Read less
    More information
    Funded Activity

    Prevention And Cure Of Type 1 Diabetes

    Funder
    National Health and Medical Research Council
    Funding Amount
    $5,289,733.00
    Summary
    The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to tes .... The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to test and identify people at risk for type 1 diabetes. They showed that the underlying disease could start years before symptoms occurred and discovered genes that determine the rate at which the underlying disease progresses. They have also found evidence that the disease may be triggered by gut viruses called rotaviruses in genetically-susceptible individuals. They showed that type 1 diabetes could be prevented in a mouse model by getting the immune system to make a protective response to insulin, and then went on to apply this in at-risk humans in a controlled trial of intranasal insulin, the first of its kind. They have used genetic techniques not only to pinpoint the mechanisms responsible for killing the beta cells but also to modify the beta cells to make them resistant to attack by these mechanisms. The multidisciplinary approach of the team will be directed to further understanding the genetic and environmental factors underlying type 1 diabetes and the immune mechanisms, particularly involving special white blood cells called T cells, that kill beta cells. A molecular target of the immune attack, the parent of insulin called proinsulin, will be used, paradoxically, as a tool to regulate the immune system and avert the attack. This will be achieved by giving proinsulin via the mucosa of the naso-respiratory tract or via the bone marrow-derived stem cells, initiallyin the mouse model as a test of feasibility for human application. In parallel with these approaches to prevention, specially constructed viruses will be used to transfer several new genes into beta cells to improve their resistance to immune attack, so that they can be transplanted into people with established diabetes without the need for potentially toxic drugs that suppress the immune system overall. The integrated research of the team is helping to provide a sound, rational base for the eventual prevention and cure of type 1 diabetes.
    Read more Read less
    More information
    Funded Activity

    Prevention And Cure Of Type 1 Diabetes

    Funder
    National Health and Medical Research Council
    Funding Amount
    $11,100,869.00
    Summary
    Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Th .... Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Their multidisciplinary research is taking us closer to the prevention and cure of T1D.
    Read more Read less
    More information
    Funded Activity

    Integration Of Risk Evaluation In Cardiovascular Disease Management Programs.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $5,162,176.00
    Summary
    This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, .... This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, this provides a unique opportunity to benefit millions of Australians.
    Read more Read less
    More information
    Funded Activity

    New Evidence To Guide Decisions About The Prevention And Treatment Of Common Cardiovascular Diseases.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $7,309,675.00
    Summary
    The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour designed to improve the prevention and treatment of heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and most other countries in the region. While there are many established treatment and prevention strategies for these conditions there remains great potential for further advances to be made, which might avert very large .... The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour designed to improve the prevention and treatment of heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and most other countries in the region. While there are many established treatment and prevention strategies for these conditions there remains great potential for further advances to be made, which might avert very large numbers of premature deaths and serious disabling outcomes. This Program of research seeks to provide new information that will give patients, doctors and policy makers innovative options for the treatment and prevention of heart attack and stroke. The Program will incorporate two main elements: observational studies and randomised controlled trials. The observational studies will establish the precise importance of each of the main causes of cardiovascular diseases (such as diabetes, blood pressure, smoking and cholesterol) at different ages, in different ethnic groups and in different geographic regions. Furthermore, these studies will also define the relative importance of established and novel risk factors for cardiovascular disease, providing important new information about how resources for prevention should be directed. The large-scale trials will provide evidence about the effectiveness and safety of a range of new cardiovascular disease prevention and treatment strategies. The work will build on the team�s very successful approach of evaluating the effects of established interventions in high-risk groups for whom those particular treatments are not currently indicated.The Program will also include studies that address the critical issue of translating health research findings into practice _ in terms of health policy, clinical practice and consumer behaviour. A particular focus involves the application and evaluation of novel Internet technologies for promoting best practice. The methodologies used by the team will ensure that the evidence generated by the Program is as precise and reliable as possible, in order to provide a sound base to guide decisions about changes in health care policy and practice. The research findings will have direct relevance to the healthcare needs of millions of Australians within the next five years, and the impact of the work will be assured by the development of implementation and dissemination plans for each major component of the Program.
    Read more Read less
    More information
    Funded Activity

    Molecular Determinants Of Risk, Progression And Treatment Response In Melanoma

    Funder
    National Health and Medical Research Council
    Funding Amount
    $8,381,820.00
    Summary
    Melanoma is a major Australian health problem. NSW figures for 2002 show it to be the second most common cancer in men and women. It has a disproportionately heavy impact on productive years of the life of young Australians because it is the commonest cancer in those aged 15-45 years. The investigators are all associated with the Sydney Melanoma Unit (SMU), the world�s largest clinical service dedicated to the treatment of melanoma, treating >1200 new melanoma patients annually. We have also .... Melanoma is a major Australian health problem. NSW figures for 2002 show it to be the second most common cancer in men and women. It has a disproportionately heavy impact on productive years of the life of young Australians because it is the commonest cancer in those aged 15-45 years. The investigators are all associated with the Sydney Melanoma Unit (SMU), the world�s largest clinical service dedicated to the treatment of melanoma, treating >1200 new melanoma patients annually. We have also recruited large cohorts of individuals with high susceptibility to melanoma, both familial and population-based, throughout southeastern Australia. We aim to utilise these unique, internationally-recognised resources to develop a scientific basis for 1) improved management of individuals at high risk for development and progression of melanoma, and 2) improved treatment of patients with early and disseminated melanoma. We will base this on consolidation of existing collaborative research into molecular predictors of risk, progression and treatment response in melanoma.
    Read more Read less
    More information
    Funded Activity

    Pathways To Diabetes Prevention

    Funder
    National Health and Medical Research Council
    Funding Amount
    $11,200,494.00
    Summary
    Type 2 diabetes (T2D) is threatening the health of this nation and if unchecked will cripple our health care system. There are several problems: (1) The incidence of T2D is growing and we do not fully know why; (2) T2D involves defective insulin action but how insulin works normally is still unclear; (3) much research in this area is performed in laboratory cells or animals and the translation of this research to the human disease is yet to be fully realised; and (4) current therapies and diagno .... Type 2 diabetes (T2D) is threatening the health of this nation and if unchecked will cripple our health care system. There are several problems: (1) The incidence of T2D is growing and we do not fully know why; (2) T2D involves defective insulin action but how insulin works normally is still unclear; (3) much research in this area is performed in laboratory cells or animals and the translation of this research to the human disease is yet to be fully realised; and (4) current therapies and diagnostic markers for early disease prediction are inadequate. Our goal is to make progress in each of these areas.
    Read more Read less
    More information
    Funded Activity

    IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES

    Funder
    National Health and Medical Research Council
    Funding Amount
    $7,212,064.00
    Summary
    Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using .... Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.
    Read more Read less
    More information

    Showing 1-10 of 11 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback